title: Comment on "Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study," by Kahl et al., Cancer Investigation, 2005, 23(1), pp. 13-18.
authors.forename: Mitchell
authors.initials: M
authors.lastname: Smith
authors.forename: Hossein
authors.initials: H
authors.lastname: Borghaei
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D017239:Paclitaxel / Q000009:adverse effects*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel